Next Article in Journal
Three New Sesquiterpene Glycosides from the Rhizomes of Trillium tschonoskii
Next Article in Special Issue
The Role of Kinase Modulators in Cellular Senescence for Use in Cancer Treatment
Previous Article in Journal
Tetrabutylammonium Iodide–Promoted Thiolation of Oxindoles Using Sulfonyl Chlorides as Sulfenylation Reagents
Previous Article in Special Issue
Synthesis and Evaluation of Novel 2-Pyrrolidone-Fused (2-Oxoindolin-3-ylidene)methylpyrrole Derivatives as Potential Multi-Target Tyrosine Kinase Receptor Inhibitors
Article Menu
Issue 8 (August) cover image

Export Article

Open AccessReview
Molecules 2017, 22(8), 1287; doi:10.3390/molecules22081287

Recent Advances in the Inhibition of p38 MAPK as a Potential Strategy for the Treatment of Alzheimer’s Disease

Department of Pharmacy, College of Pharmacy, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Korea
*
Author to whom correspondence should be addressed.
Received: 8 July 2017 / Revised: 27 July 2017 / Accepted: 1 August 2017 / Published: 2 August 2017
(This article belongs to the Special Issue Kinase Inhibitors)
View Full-Text   |   Download PDF [2375 KB, uploaded 2 August 2017]   |  

Abstract

P38 mitogen-activated protein kinase (MAPK) is a crucial target for chronic inflammatory diseases. Alzheimer’s disease (AD) is characterized by the presence of amyloid plaques and neurofibrillary tangles in the brain, as well as neurodegeneration, and there is no known cure. Recent studies on the underlying biology of AD in cellular and animal models have indicated that p38 MAPK is capable of orchestrating diverse events related to AD, such as tau phosphorylation, neurotoxicity, neuroinflammation and synaptic dysfunction. Thus, the inhibition of p38 MAPK is considered a promising strategy for the treatment of AD. In this review, we summarize recent advances in the targeting of p38 MAPK as a potential strategy for the treatment of AD and envision possibilities of p38 MAPK inhibitors as a fundamental therapeutics for AD. View Full-Text
Keywords: p38 mitogen activated protein kinase (MAPK); kinase inhibitor; Alzheimer’s disease; tau phosphorylation; neuroinflammation; amyloid beta p38 mitogen activated protein kinase (MAPK); kinase inhibitor; Alzheimer’s disease; tau phosphorylation; neuroinflammation; amyloid beta
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Lee, J.K.; Kim, N.-J. Recent Advances in the Inhibition of p38 MAPK as a Potential Strategy for the Treatment of Alzheimer’s Disease. Molecules 2017, 22, 1287.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top